Actively Recruiting

Phase Not Applicable
Age: 18Years - 90Years
All Genders
ID04987086

A Prospective, Multicenter Study of Diagnostic Efficiency of 68Ga-PSMA PET in Patients With Locally Advanced and Advanced Renal Cell Carcinoma

Led by Xijing Hospital · Updated on 2026-03-11

300

Participants Needed

9

Research Sites

52 weeks

Total Duration

On this page

Sponsors

X

Xijing Hospital

Lead Sponsor

A

Air Force Military Medical University, China

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the diagnostic effectiveness of 68Ga-PSMA PET scans compared to enhanced CT scans in detecting metastatic lesions in patients with locally advanced and advanced renal cell carcinoma. The study also aims to see if 68Ga-PSMA PET can influence treatment decisions for these patients. This prospective, multicenter trial is sponsored by Xijing Hospital and focuses on improving diagnosis and management for renal cancer with metastases. Participants in the study will receive both a 68Ga-PSMA PET scan and an enhanced CT scan simultaneously to compare their abilities to detect cancer spread. This diagnostic approach helps assess the additional value that 68Ga-PSMA PET may provide over standard CT imaging. The study does not involve any masking or placebo groups and includes only patients who meet specific clinical and imaging criteria. During the study, patients will undergo imaging within six weeks after diagnosis, and researchers will track how the 68Ga-PSMA PET results affect treatment choices. The primary measurement is the additional diagnostic value of the PSMA PET compared to CT over two years. Secondary outcomes include how often the PET scan changes treatment decisions. The study monitors patient safety and adherence, with a planned follow-up period to evaluate outcomes until December 2027.

CONDITIONS

Brief Title

68Ga-PSMA PET in the Renal Cell Carcinoma

Who Can Participate

Age: 18Years - 90Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults with 2017 AJCC renal cell carcinoma stage III or IV
  • Suspicious metastases found on contrast-enhanced CT staging
  • No known peripheral or central venous problems
  • Able to undergo 68Ga PSMA PET/CT imaging within 6 weeks after diagnosis
  • Signed informed consent for voluntary participation
Not Eligible

You will not qualify if you...

  • Age 18 years or younger
  • Unable to lie flat for PET/CT examination
  • Contraindications for 68Ga PSMA ligands
  • History of other malignant tumors in past 2 years or complications affecting test
  • Impaired renal function or currently on hemodialysis

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Within 6 weeks after diagnosis

Participants undergo 68Ga PSMA PET and enhanced CT imaging to assess renal cell carcinoma and suspicious metastases.

1 visit (in-person)

Long-term Monitoring

Duration - 2 years

Participants are followed for up to 2 years to evaluate the diagnostic value of 68Ga PSMA PET / CT and changes in treatment decision-making.

Follow-up visits as needed

Trial Site Locations

Total: 9 locations

1

The First Hospital of Lanzhou University

Lanzhou, Gansu, China

Actively Recruiting

2

General Hospital of Ningxia Medical University

Yinchuan, Ningxia, China

Actively Recruiting

3

Qinghai University Affiliated Hospital

Xining, Qinghai, China

Actively Recruiting

4

Xijing Hospital

Xi'an, Shaan'xi, China, 710032

Actively Recruiting

5

Weinan Central Hospital

Weinan, Shaanxi, China

Actively Recruiting

6

Shaanxi Provincial People's Hospital

Xi'an, Shaanxi, China

Actively Recruiting

7

Xijing 986 Hospital

Xi'an, Shaanxi, China

Actively Recruiting

8

The Second Affiliated Hospital of Shaanxi University of Chinese Medicine

Xianyang, Shaanxi, China

Actively Recruiting

9

Affiliated Hospital of Yan'an University

Yan’an, Shaanxi, China

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Similar Trials

A First-in-Human, Phase I/II PET Imaging Study of 64Cu-GRIP ...

Prostate Cancer

Actively Recruiting

1 location

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced...

Advanced Solid Tumor

Actively Recruiting

12 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here